A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer.

M, Hamid; LK, Heilbrun; J, Maier; K, Devisetty; I, Connolly; I, Kaufman; K, Dobson; MK, Herroon; D, Smith; S, Sampson; I, Podgorski; EI, Heath

doi:10.1016/j.adro.2021.100679

Public

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer.

Shared by NobleBlocks on Mar 3, 2021 • 12:00 AM UTC

Authors:

Hamid M

Heilbrun LK

Maier J

Abstract

Purpose This study aimed to evaluate a combination of radiation therapy (RT), androgen deprivation therapy (ADT), and pexidartinib (colony-stimulating factor 1 receptor [CSF1R]) inhibitor in men with intermediate- and high-risk prostate cancer. CSF1R signaling promotes tumor infiltration and surviva...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!